A Phase 2 interventional study of Psilocybin 25 mg and Placebo in Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD), sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Centre for Addiction and Mental Health · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing psilocybin in Depressive Disorder, Major — 11 open to participants now, 16 under way, 4 of them phase 3. Psilocybin · Depressive Disorder, Major.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, this one is the 17th largest by planned enrollment, is one of 5 that started in 2026, is one of 25 in phase 2, reaches primary completion later than 8 of the 15 other live ones, and was the 26th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →11 of the 31 studies testing psilocybin in Depressive Disorder, Major are open now, in 7 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–75
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
University Medical Center Groningen · Sites in Czechia, Denmark, Netherlands and 1 more country
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–64
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 30 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 35 across the 31 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health: 10 open now, 13 under way, none of them phase 3. Of 34 finished, 0 (0%) have results posted.
Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 34th largest by planned enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, reaches primary completion later than 9 of the 12 other live ones, and was the 47th registered.
Centre for Addiction and Mental Health’s Depressive Disorder, Major studies by the year they started, since 2001.
4 of the studies testing psilocybin in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT05947383Sunstone MedicalTwo Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | 2027-04-30 |
| NCT07479550Stanford UniversityStudy of Psilocybin Under Anesthesia Controlled by EEG | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies testing psilocybin in Depressive Disorder, Major, from their registry updates:
Among Centre for Addiction and Mental Health’s 48 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is:
- What is the feasibility and safety of administering PAT in adults with MDD-AUD by evaluating recruitment, retention, tolerability, and safety?
Researchers will compare the psilocybin (25 mg) and placebo groups to see if there are any significant differences in frequency of dropouts or serious adverse events.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant is administered one oral capsule (25 mg psilocybin) with water.
Drug: Psilocybin 25 mg
Participant is administered one oral capsule (0 mg psilocybin) with water.
Drug: Placebo
Participants will orally consume Psilocybin (25 mg) with water.
Participants will orally consume placebo matching the intervention with water.
Adherence
Although all administration of psilocybin will be administered by qualified staff, the investigators will measure adherence through visit compliance (i.e., missed visits).
Time frame: Week 2 (Visit 4)
Montgomery-Asberg Depression Rating Scale (MADRS)
Used to assess changes in depressive symptoms on a 10-item scale with each item rated on a scale of 0-6. Higher scores indicate greater severity of symptoms.
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Hamilton Depression Rating Scale (HAMD-17)
Used to assess changes in depressive symptoms using 3-point (0-2) or 5-point (0-4) Likert scales. Higher scores indicate greater severity of symptoms.
Time frame: 4-week post dose; week 26.
Quick Inventory of Depressive Symptomatology - Self Report (QUIDS-SR)
Used to assess changes in depressive symptoms with a minimum score of 0 to a maximum score of 27.
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Alcohol Timeline Followback (TLFB)
To monitor alcohol consumption, heavy drinking days, drinks per day, drinks per drinking day, percent very heavy drinking days, percent participants with no heavy drinking days, and abstinent percent will be measured.
Time frame: Baseline; week 2 (visit 3); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Clinical Institute Withdrawal Assessment (CIWA)
Used to assess alcohol withdrawal symptoms. Scores range from 0 to 67 with higher scores indicating greater severity of withdrawal symptoms.
Time frame: Baseline; week 2 (visit 3); week 2 (visit 4); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Prediction of Alcohol Withdrawal Severity Scale (PAWSS)
Used to assess risk of alcohol withdrawal symptoms using a 10-item scale with the total score ranging from 0 to 10. Higher scores indicate greater risk of withdrawal symptoms.
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Penn Alcohol Craving Scale (PACS)
Used to assess history, frequency, and consequences of alcohol use. Scores range from 0 to 30 with higher scores indicating greater craving.
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Addiction Severity Index (ASI)
Used to assess history, frequency, and consequences of alcohol use
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
5 Dimensional Altered States of Consciousness (5-DASC)
Used to assess subjective effects of psilocybin. Minimum value of 0 to maximum value of 100, with higher scores representing greater reports of alterations to normal waking consciousness.
Time frame: Week 2 (visit 4).
Psychological Insight Questionnaire (PIQ)
Used to assess subjective effects of psilocybin. Contains 23 items rated on a 5-point Likert scale. Higher scores generally indicate greater intensity of psychological insight.
Time frame: Week 2 (visit 4).
Mystical Experience Questionnaire (MEQ)
Used to assess subjective effects of psilocybin. Contains 30 items rated on a 5-point Likert scale. Higher scores indicate greater mystical experience.
Time frame: Week 2 (visit 4).
Challenging Experience Questionnaire (CEQ)
Used to assess subjective effects of psilocybin. Contains 26 items rated on a 5-point Likert scale. Higher scores generally indicate more challenging experience or distress.
Time frame: Week 2 (visit 4).
General Anxiety Disorder-7th edition (GAD-7)
Used to assess anxiety-related symptoms. Scores range from 0 to 21 with higher scores indicating greater severity of anxiety symptoms.
Time frame: Baseline; week 26.
State Trait Anxiety Index (STAI)
Used to assess anxiety-related symptoms. Scores range from 20 to 80 with higher scores indicating greater severity of anxiety symptoms.
Time frame: Baseline; week 26.
World Health Organization Quality of Life Questionnaire Brief Version (WHOQOL-BREF)
Used to assess overall quality of life. Scores range from 0 to 100 with higher scores indicating greater quality of life.
Time frame: Baseline; week 26.
Big Five Inventory (BFI)
Used to assess personality. Contains 44 items with each item rated on a five-point Likert scale from 1 (disagree a lot) to 5 (agree a lot). Higher scores in each trait indicates stronger association to the trait.
Time frame: Baseline; week 26.
Pittsburgh Sleep Quality Index (PSQI)
Used to assess quality of sleep. Score ranges from 0 to 21 with higher scores indicating greater disturbance to sleep.
Time frame: Baseline; week 26.
Acceptance & Action Questionnaire II (AAQ-II)
Used to assess psychological flexibility. There are 7-items each rated on a 7-point Likert scale. Higher scores indicate greater psychological inflexibility.
Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post-dose; 4-week post-dose; week 10; week 14; week 18; week 22; week 26.
Stanford Expectations of Treatment Scale (SETS)
Used to assess participants' positive and negative treatment expectancies. Rated on a 7-item Likert scale, with minimum score of 6, and maximum score of 42. Higher scores generally indicate greater expectations for positive expectancy scores and greater concerns for negative expectancy scores.
Time frame: Baseline
Working Alliance Inventory (WAI)
Used to assess the participants' therapeutic relationship with their therapists. Scores range from 12 to 60 with higher scores indicating stronger therapeutic alliance.
Time frame: Week 2 (visit 3); 1-day post dose; 1-week post dose.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Centre for Addiction and Mental Health →